Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS), are incurable and debilitating conditions characterized by progressive degeneration of speciﬁc neurons within the brains of aﬀected individuals. Neurodegenerative diseases have become an enormous economic burden that is projected to grow signiﬁcantly over the next few decades in the absence of any new therapeutic interventions.
Drugs for the central nervous system, including neurodegenerative diseases, that entered clinical development, have a considerably lower probability of reaching the marketplace (7%) than the industry average across other therapeutic areas (15%), and require a longer time for development and regulatory approval (average of 12.6 years) compared with most other diseases (e.g., 6.3 years for cardiovascular and 7.5 years for gastrointestinal indications).
In this compound library, TargetMol collects 902 compounds related to neurodegenerative diseases having therapeutic effect or acting on neurodegenerative disease-related targets.
|100 μL * 10 mM (in DMSO)||14668.00|
|250 μL * 10 mM (in DMSO)||24560.00|